Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced a private offering of senior secured notes to fund the proposed acquisition of GW Pharmaceuticals and refinance existing debt. The offering is not conditioned on the acquisition's closing. If the acquisition does not occur by August 3, 2021, or the transaction agreement is terminated, the notes will be redeemed at 100% of their principal plus interest. The notes will only be offered to qualified institutional buyers and are exempt from registration under the Securities Act.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced positive results from the Phase 3 study of Xywav for treating idiopathic hypersomnia, presented at the 2021 AAN Annual Meeting. The results indicate significant improvements in the Epworth Sleepiness Scale (ESS) and Idiopathic Hypersomnia Severity Scale (IHSS) scores, showing the potential of Xywav as a treatment for this chronic sleep disorder. The FDA has accepted a supplemental New Drug Application for Xywav and granted it Priority Review.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will announce its 2021 first quarter financial results on May 4, 2021, after market close. A live audio webcast will follow at 4:30 p.m. ET for discussion of the results and business updates. Interested parties can access the webcast via the company's website. Jazz Pharmaceuticals focuses on developing medicines for serious diseases, particularly in neuroscience and oncology, serving patients in over 90 countries.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has received Priority Review designation from the FDA for its supplemental New Drug Application (sNDA) for Xywav, an oral solution aimed at treating idiopathic hypersomnia in adults. The FDA will file the sNDA on April 13, 2021, with a decision expected by August 12, 2021. The Phase 3 clinical study met its primary endpoint, showing significant improvements in patients' daytime sleepiness levels. The results will be presented at the 2021 AAN Annual Meeting on April 20, 2021.
Jazz Pharmaceuticals has received FDA approval for a revised label for Vyxeos (daunorubicin and cytarabine), allowing its use in treating newly-diagnosed therapy-related acute myeloid leukemia (t-AML) and AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged 1 year and older. This approval is based on safety data from two trials by the Children's Oncology Group and Cincinnati Children's Hospital, demonstrating a critical need for effective therapies in this demographic. Vyxeos is significant in the fight against AML, a rare yet serious cancer.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will participate in the 10th Annual J.P. Morgan Napa Valley Forum on March 29, 2021. CEO Bruce Cozadd will deliver a corporate presentation, including business and financial updates, at 12:00 p.m. EST. The presentation can be accessed via a live audio webcast from the company's website, with an archive available for one week post-event. Jazz focuses on developing and commercializing life-changing medicines in areas like neuroscience and oncology, serving patients in over 90 countries.
On March 18, 2021, Jazz Pharmaceuticals (Nasdaq: JAZZ) partnered with the Hypersomnia Foundation to launch the 'I Have IH' campaign. This initiative aims to raise awareness and understanding of idiopathic hypersomnia (IH), a debilitating neurologic sleep disorder. A recent survey of 305 healthcare providers revealed that only 36% believe others adequately understand IH, highlighting a significant education gap. With misdiagnosis common and delays in accurate diagnosis lasting up to 15 years, the campaign seeks to empower patients and enhance discussions with their healthcare teams.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced participation in the Cowen 41st Annual Healthcare Conference, with CEO Bruce Cozadd presenting on March 2, 2021, at 12:50 p.m. EST. The webcast will cover a business and financial update and can be accessed through their website.
Archived audio of the presentation will be available for at least a week following the event. Jazz Pharmaceuticals focuses on developing life-changing medicines in neuroscience and oncology, serving patients in over 90 countries.
Jazz Pharmaceuticals (Nasdaq: JAZZ) reported a 9% revenue increase in 2020, totaling $2.36 billion, driven by successful product launches like Zepzelca and Xywav. GAAP net income for 2020 was $238.6 million, or $4.22 per diluted share, down from $523.4 million in 2019. The company projects 2021 revenues between $2.55 billion and $2.7 billion, emphasizing growth in neuroscience and oncology sectors. Additionally, Jazz is set to acquire GW Pharmaceuticals for $7.2 billion, aiming to enhance its neuroscience portfolio.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in the Leerink 10th Annual Global Healthcare Conference. CEO Bruce Cozadd will present on February 24, 2021, at 1:40 p.m. EST. The presentation will include a business and financial update, accessible via a live audio webcast on the Jazz Pharmaceuticals website. An archive will be available for at least a week post-presentation. Jazz is focused on developing innovative medications in neuroscience and oncology, with a global presence serving patients in over 90 countries.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
